ISRCTN05581879
Completed
未知
Angiotensin converting enzyme (ACE) inhibition and mechanisms of skeletal muscle weakness in chronic obstructive pulmonary disease (COPD): a double-blind, randomised, placebo-controlled, parallel trial
Imperial College London (UK)0 sites80 target enrollmentOctober 31, 2008
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Imperial College London (UK)
- Enrollment
- 80
- Status
- Completed
- Last Updated
- 6 years ago
Overview
Brief Summary
2014 results in: http://www.ncbi.nlm.nih.gov/pubmed/24556825
Investigators
Eligibility Criteria
Inclusion Criteria
- •Adult patients (greater than 18 years, either sex) with COPD diagnosed according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria. Only patients with quadriceps weakness will be enrolled into this randomised controlled trial (RCT).
Exclusion Criteria
- •1\. Clinically unstable patients (within one month of exacerbation)
- •2\. Those with a permanent pacemaker (which is a contraindication to magnetic stimulation), or significant co\-morbidity
- •3\. Patients with an accepted indication for ACE inhibition (left ventricular dysfunction, diabetes) or a contraindication such as renovascular disease
- •4\. Creatinine clearance (estimated) less than 50 ml/min
- •5\. Hypotension
- •6\. Use of anticoagulants (contraindication to biopsy) or angiotensin converting enzyme inhibitor (ACE\-I) or angiotensin II (ATII) receptor antagonists
- •7\. Allergy to ACE\-I
- •8\. Pregnancy
- •9\. Patients who have participated in a pulmonary rehabilitation programme within the past three months
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Angiotensin Converting Enzyme (ACE) inhibitors in renal transplant recipients with left ventricular hypertrophyISRCTN94487168Azienda Ospedaliera Universitaria S.Martino (Italy)70
Completed
Phase 2
Effects of Angiotensin-Converting Enzyme Inhibitor (Ramipril) Therapy on Blood Vessel InflammationAtherosclerosisCoronary DiseaseVasculitisNCT00005928National Heart, Lung, and Blood Institute (NHLBI)25
Completed
Not Applicable
Effect of angiotensin-converting enzyme inhibitors on systemic inflammation and myocardial sympathetic innervation in normotensive patients with type two diabetes mellitusType two Diabetes Mellitus (DM)Nutritional, Metabolic, EndocrineDiabetes mellitusISRCTN76608550Heraklion University Hospital (Greece)62
Completed
Not Applicable
Angiotensin Converting Enzyme (ACE) inhibition for the preservation of renal function and patient survival in kidney transplantatioChronic kidney disease in renal transplant patientsUrological and Genital DiseasesChronic kidney diseaseISRCTN78129473Ottawa Hospital Research Institute (OHRI) (Canada) - formerly Ottawa Health Research Institute528
Active, not recruiting
Phase 1
Angiotensin Converting Enzyme Inhibitor (ACE) Induced AngioedemaBERINERTRandomized, double-blind, two arms, multicenter, Phase III study of Berinert for treatment of ACE induced AngioedemaAngiotensin – Converting – Enzyme – Inhibitors (ACEi) are used in the treatment of several types of cardiovascular and renal diseases. A known side effect of ACEi are angioedema of the head and neck region. These can lead to severe dyspnoea and the need for intubation and are thought to be bradykinin mediated. Up until now there is no study-evaluated conservative therapeutic concept for the treatment of these patients.MedDRA version: 18.1Level: HLTClassification code 10002425Term: AngioedemasSystem Organ Class: 100000004870Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]EUCTR2012-001670-28-DEMedizinische Fakultät der Technischen Universität München52